Notably, in the terminally exhausted state where PD-1 antibody treatment was ineffective, such as CAR-T cells from donor 1 after 3 rounds of tumor stimulation (Figures 1F and 1G), miltefosine was still able to enhance CAR-T cell activity (Figure 3D). This evidence concerns the gene PDCD1 and neoplasm.